Enanta Pharmaceuticals, Inc. (ENTA) EPS Estimated At $0.04

January 23, 2018 - By Peter Erickson

 Enanta Pharmaceuticals, Inc. (ENTA) EPS Estimated At $0.04
Investors sentiment increased to 1.6 in 2017 Q3. Its up 0.75, from 0.85 in 2017Q2. It increased, as 9 investors sold Enanta Pharmaceuticals, Inc. shares while 31 reduced holdings. 16 funds opened positions while 48 raised stakes. 12.10 million shares or 2.87% more from 11.77 million shares in 2017Q2 were reported.
Weiss Multi reported 0.05% stake. Adams Diversified Equity Fund holds 20,000 shares or 0.05% of its portfolio. Public Sector Pension Invest Board stated it has 8,835 shares. 1,700 are held by Pacad Ltd. Gsa Limited Liability Partnership stated it has 19,700 shares or 0.06% of all its holdings. New York State Common Retirement Fund, a New York-based fund reported 49,418 shares. Price T Rowe Assoc Md has invested 0% in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA). Blackrock owns 2.25M shares or 0.01% of their US portfolio. State Of Alaska Department Of Revenue owns 2,750 shares. Northern Trust holds 195,523 shares. Guggenheim Cap Ltd Llc reported 0% stake. 1,772 were reported by Pinebridge Investments Lp. The Ohio-based Strs Ohio has invested 0% in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA). Citigroup Incorporated accumulated 24,482 shares. 32,167 are owned by Ajo Lp.

Analysts expect Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) to report $0.04 EPS on February, 14.They anticipate $0.30 EPS change or 115.38 % from last quarter’s $-0.26 EPS. ENTA’s profit would be $764,814 giving it 441.94 P/E if the $0.04 EPS is correct. After having $1.86 EPS previously, Enanta Pharmaceuticals, Inc.’s analysts see -97.85 % EPS growth. The stock increased 5.04% or $3.39 during the last trading session, reaching $70.71. About 164,848 shares traded. Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) has risen 40.91% since January 23, 2017 and is uptrending. It has outperformed by 24.21% the S&P500.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Ratings Coverage

Among 5 analysts covering Enanta Pharmaceuticals Inc (NASDAQ:ENTA), 2 have Buy rating, 1 Sell and 2 Hold. Therefore 40% are positive. Enanta Pharmaceuticals Inc had 20 analyst reports since August 7, 2015 according to SRatingsIntel. On Monday, November 20 the stock rating was maintained by Robert W. Baird with “Hold”. The firm has “Mkt Outperform” rating given on Friday, October 23 by JMP Securities. The rating was downgraded by Zacks to “Buy” on Friday, August 7. The company was downgraded on Saturday, August 8 by TheStreet. Barclays Capital downgraded the stock to “Underweight” rating in Friday, October 23 report. As per Tuesday, August 8, the company rating was maintained by Robert W. Baird. On Monday, November 20 the stock rating was maintained by RBC Capital Markets with “Buy”. The rating was maintained by JP Morgan with “Overweight” on Tuesday, August 9. The stock of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) has “Sector Perform” rating given on Tuesday, January 2 by RBC Capital Markets. Robert W. Baird maintained the stock with “Hold” rating in Friday, October 20 report.

Enanta Pharmaceuticals, Inc., a biotechnology company, focuses on discovering and developing small molecule drugs for the treatment of viral infections and liver diseases. The company has market cap of $1.35 billion. The company??s research and development focuses on disease targets: hepatitis B virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and respiratory syncytial virus. It has a 77.7 P/E ratio. It has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus.

More notable recent Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) news were published by: Seekingalpha.com which released: “Enanta Pharmaceuticals: Updates To Thesis” on August 06, 2017, also Seekingalpha.com with their article: “Enanta Pharmaceuticals’ (ENTA) CEO Jay Luly on Fiscal Q3 2017 Results …” published on August 08, 2017, Seekingalpha.com published: “Enanta Pharmaceuticals’ (ENTA) CEO Jay Luly on Fiscal Q4 2017 Results …” on November 21, 2017. More interesting news about Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) were released by: Businesswire.com and their article: “Enanta Pharmaceuticals to Provide Updates on its Research and Development …” published on January 05, 2018 as well as Businesswire.com‘s news article titled: “Enanta Pharmaceuticals Announces New Data Presentations on EDP-305, an FXR …” with publication date: September 27, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.